AstraZeneca has warned it could face a fine in China over possible unpaid import taxes, as it revealed strong sales of cancer drugs helped lift revenues higher. The FTSE 100-listed drugmaker said ...

UK drugmaker AstraZeneca overcame a drop in sales in China and the arrest of its top executive in the country to deliver an 18 per cent increase in revenues in the final quarter of 2024.

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...

Paul Tunnah sat down with AstraZeneca's vice president of sustainability strategy and engagement Jim Massey to discuss how the global pharma company is embracing a green future. There has been a ...

AstraZeneca's Farxiga reduced the risk of hospitalisation and death in people with all types of heart failure in the DELIVER trial, which could dramatically increase the population of patients ...

AstraZeneca has agreed a deal worth up to $247 million with US generative artificial intelligence (GenAI) company Absci that will focus on the discovery of a new antibody-based drug for cancer.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from Chinese biotech Usynova for $24 million upfront. The compound – called UA022 – targets the ...

Lord Storey formerly served as leader of Liverpool City Council A Liberal Democrat peer has accused the government of favouring the south-east of England over Merseyside after AstraZeneca pulled ...